Translate Bio (TBIO) Sees Large Volume Increase

Shares of Translate Bio Inc (NASDAQ:TBIO) saw strong trading volume on Friday . 363,602 shares traded hands during trading, an increase of 87% from the previous session’s volume of 193,995 shares.The stock last traded at $8.30 and had previously closed at $7.88.

Several equities analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Translate Bio in a research report on Monday, December 24th. They set a “buy” rating and a $21.00 price target for the company. ValuEngine lowered shares of Translate Bio from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $22.75.

The company has a debt-to-equity ratio of 0.91, a quick ratio of 16.71 and a current ratio of 16.72.

A number of large investors have recently modified their holdings of the business. FMR LLC boosted its position in Translate Bio by 6.8% during the fourth quarter. FMR LLC now owns 6,771,313 shares of the company’s stock worth $50,785,000 after purchasing an additional 433,952 shares during the period. Baupost Group LLC MA boosted its position in Translate Bio by 237.5% during the third quarter. Baupost Group LLC MA now owns 6,491,287 shares of the company’s stock worth $62,393,000 after purchasing an additional 4,568,211 shares during the period. Atlas Venture Advisors Inc. bought a new position in Translate Bio during the fourth quarter worth about $29,415,000. BlackRock Inc. boosted its position in Translate Bio by 130.2% during the fourth quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after purchasing an additional 555,635 shares during the period. Finally, Federated Investors Inc. PA boosted its position in Translate Bio by 12.6% during the third quarter. Federated Investors Inc. PA now owns 800,000 shares of the company’s stock worth $8,000,000 after purchasing an additional 89,805 shares during the period. Hedge funds and other institutional investors own 59.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Translate Bio (TBIO) Sees Large Volume Increase” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://transcriptdaily.com/2019/03/16/translate-bio-tbio-sees-large-volume-increase.html.

Translate Bio Company Profile (NASDAQ:TBIO)

Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.

Recommended Story: Bollinger Bands

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.